Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of New York Mellon Corp (BNY) vs 10X Genomics Inc (TXG) Price & Performance

Bank of New York Mellon CorpTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Bank of New York Mellon Corp vs 10X Genomics Inc — how do they compare? Bank of New York Mellon Corp trades at $162.95 (market cap $108.78B), while 10X Genomics Inc trades at $58.26 (market cap $7.61B). The key difference: Bank of New York Mellon Corp is far larger — about 14.3× 10X Genomics Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

BNYTXG
Market Cap
$108.78B$7.61B
Sector
FinancialsHealth
52-Week High
$162.35$58.57
52-Week Low
$101.00$11.34
Dividend Yield
1.38%
Enterprise Value
$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of New York Mellon Corp

BNY stock trades at $159.44, up 1.14% on the day, near the analyst consensus price target of $170.36. The stock shows a bullish technical trend with strong moving average signals, and fundamentals are robust with consistent earnings beats, revenue growth to $19.76B in 2025, and a net income margin of 29.96%. Recent news highlights strategic moves in digital asset infrastructure and a dividend declaration.

The outlook for BNY is positive, supported by earnings momentum and digital innovation, but risks include high investing cash outflows and interest expenses. Analyst sentiment is mixed with a slight hold bias, yet institutional upgrades and a strong ROE of 15.34% offer upside potential amid market volatility.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bank of New York Mellon Corp

BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.

Read more on BNY

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG